Analysis

2016 Global life sciences outlook

Moving forward with cautious optimism

How is the global life sciences sector addressing today’s volatile marketplace, one characterized by economic uncertainty, pricing pressures, increased demand for innovation and value, more focus on consumer engagement, and an ever-changing regulatory and risk environment?

Explore our look at the current global issues impacting the global life sciences sector, as well as a snapshot of activity in a number of geographic markets, and considerations for stakeholders as they prepare for 2016.

Download the full report

2016 Global life sciences sector outlook

Countering pricing and cost pressures

Amid the reform-driven shift to outcomes-focused, value-based payment and reimbursement systems, pharma companies may continue to bear the brunt of efforts to control costs. Companion diagnostics should continue to rapidly increase in number and application though. Organizations of all sizes are also struggling with issues that span development, manufacturing, and distribution – pressure to reduce the cost of early-stage research and development without reducing output; reduce clinical development risks while also producing high-quality data; need to reduce asset bases; optimization of outsourcing strategies; difficulty operationalizing and optimizing acquisitions; talent and leadership issues; and supply chain risks. Companies are also addressing outdated IT infrastructure challenges as they continue to adapt to the new realities of cloud, analytics, informatics mobility and outcomes measurement.

Promoting innovation

Companies are facing dual imperatives to deliver innovative therapies that address unmet patient needs and treat life-threatening conditions but also deliver profitable growth. Achieving these often-conflicting objectives is likely to require that companies transform their business and operating models and embrace disruptive technology advancements that can concurrently reduce costs and speed time to market for new products and services. From product development through manufacturing and distribution, life sciences companies are evolving their business models to engage more fully with providers and patients. Personalized medicine also continues to drive business model transformation. Digital health technology – such as telehealth, mHealth, wearables, and social media - is creating a paradigm shift in life sciences and the data is being used to transform aspects of health care that earlier seemed beyond the purview of such technologies. Mergers and acquisitions (M&A) are expected continue to be one of the life sciences sector’s principal growth strategies.

Adapting to an evolving regulatory and risk environment

Life sciences stakeholders face increasingly complex operational risks and regulatory challenges emanating from technology advances, clinician and patient expectations, and a globally connected health care market. Top-of-mind issues for the sector include cybersecurity and IT quality, regulations and compliance, drug and device safety, counterfeit drugs, and Intellectual Property (IP) protection.

Regional & country perspectives

Life sciences companies in 2016 will not only face challenges emanating from an increasingly global marketplace, there will also be regional and country-specific issues to address. Explore the latest findings. 

Sources

For a complete list of sources referenced in this outlook, please download the source list.  

  • Contact us
  • Submit an RFP
  • Life Sciences & Health care related article

    Life Sciences & Health care

    Leadership perspectives

    The Health Care Current, a weekly series published by the Deloitte US Center for Health Solutions, explores breaking news and developments in the health care industry, examines key issues facing LSHC companies and provides updates and insights on policy, regulatory, and legislative changes.

    2016 Global health care sector outlook

    Explore the top issues facing global health care organizations and stakeholders as they seek to address the most challenging issues in 2016.

    Measuring the return from pharmaceutical innovation 2015

    Macroeconomic pressures have hit the R&D returns of life sciences firms, according to new Deloitte research. Our sixth annual pharmaceutical innovation study looks at the challenges the industry faces in generating returns from its R&D investments, while highlighting lessons that can be learned.

Did you find this useful?